MedPath
HSA Approval

DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG

SIN15301P

DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG

DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG

July 20, 2017

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Regulatory Information

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Therapeutic

Prescription Only

Formulation Information

TABLET, DELAYED RELEASE

**2\. DOSAGE AND ADMINISTRATION** **2.1 Dosage Information** Initially, take two DICLECTIN delayed-release tablets orally at bedtime (Day 1). If this dose adequately controls symptoms the next day, continue taking two tablets daily at bedtime. However, if symptoms persist into the afternoon of Day 2, take the usual dose of two tablets at bedtime that night then take three tablets starting on Day 3 (one tablet in the morning and two tablets at bedtime). If these three tablets adequately control symptoms on Day 4, continue taking three tablets daily. Otherwise take four tablets starting on Day 4 (one tablet in the morning, one tablet mid-afternoon and two tablets at bedtime). The maximum recommended dose is four tablets (one in the morning, one in the mid-afternoon and two at bedtime) daily. Take on an empty stomach with a glass of water _\[see Clinical Pharmacology (12.3)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_. Swallow tablets whole. Do not crush, chew, or split DICLECTIN tablets. Take as a daily prescription and not on an as needed basis. Reassess the woman for continued need for DICLECTIN as her pregnancy progresses.

ORAL

Medical Information

**1\. INDICATIONS AND USAGE** DICLECTIN is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. **Limitations of Use** DICLECTIN has not been studied in women with hyperemesis gravidarum.

**4\. CONTRAINDICATIONS** DICLECTIN is contraindicated in women with any of the following conditions: - Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation. - Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of DICLECTIN _\[see Drug Interactions (7.1)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.

R06AA59

doxylamine, combinations

Manufacturer Information

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Duchesnay Inc.

Active Ingredients

Doxylamine Succinate

10mg

Doxylamine

Pyridoxine Hydrochloride

10mg

Pyridoxine

Documents

Package Inserts

Diclectin Delayed Release Tablets PI.pdf

Approved: August 27, 2018

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG - HSA Approval | MedPath